All news from Obstetrics & Gynaecology

Breast Cancer Patients Lack Cardiac Monitoring

Less than half of the women with early breast cancer underwent recommended cardiac monitoring after receiving trastuzumab, a drug that has redefined the treatment of HER2-positive disease but also carries a higher risk for cardiotoxicity.

The rate of heart failure (HF) was 8.3% in women who took trastuzumab-based chemotherapy vs 2.7% in those who did not (P < .001). Rates were roughly halved in patients using vs not using anthracyclines an older class of cancer drugs also associated with cardiotoxicity (4.6% vs 4.0%; P = .048).

The study was published in JACC Cardiovascular Interventions.